Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Lebrikizumab> ?p ?o. }
Showing items 1 to 61 of
61
with 100 items per page.
- Lebrikizumab abstract "Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppresive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. The drug was created by Tanox under the name TNX-650, and a phase I clinical trial for refractory Hodgkin’s lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a Phase II clinical trial for the treatment of asthma.".
- Lebrikizumab atcPrefix "none".
- Lebrikizumab casNumber "953400-68-5".
- Lebrikizumab fdaUniiCode "U9JLP7V031".
- Lebrikizumab wikiPageID "12597718".
- Lebrikizumab wikiPageRevisionID "604290219".
- Lebrikizumab atcPrefix "none".
- Lebrikizumab c "6434".
- Lebrikizumab casNumber "953400".
- Lebrikizumab chemspiderid "NA".
- Lebrikizumab h "9972".
- Lebrikizumab hasPhotoCollection Lebrikizumab.
- Lebrikizumab kegg "D09633".
- Lebrikizumab legalStatus "Investigational".
- Lebrikizumab mabType "mab".
- Lebrikizumab n "1700".
- Lebrikizumab o "2034".
- Lebrikizumab pubchemsubstance "124490373".
- Lebrikizumab routesOfAdministration Subcutaneous_injection.
- Lebrikizumab s "50".
- Lebrikizumab source "zu".
- Lebrikizumab synonyms "MILR1444A, RG3637".
- Lebrikizumab target Interleukin_13.
- Lebrikizumab type "mab".
- Lebrikizumab unii "U9JLP7V031".
- Lebrikizumab verifiedfields "changed".
- Lebrikizumab verifiedrevid "458270514".
- Lebrikizumab watchedfields "changed".
- Lebrikizumab subject Category:Monoclonal_antibodies.
- Lebrikizumab type Abstraction100002137.
- Lebrikizumab type Antibody115027189.
- Lebrikizumab type Chemical114806838.
- Lebrikizumab type Compound114818238.
- Lebrikizumab type Macromolecule114944888.
- Lebrikizumab type Material114580897.
- Lebrikizumab type Matter100020827.
- Lebrikizumab type Molecule114682133.
- Lebrikizumab type MonoclonalAntibodies.
- Lebrikizumab type MonoclonalAntibody115029781.
- Lebrikizumab type OrganicCompound114727670.
- Lebrikizumab type Part113809207.
- Lebrikizumab type PhysicalEntity100001930.
- Lebrikizumab type Protein114728724.
- Lebrikizumab type Relation100031921.
- Lebrikizumab type Substance100019613.
- Lebrikizumab type Thing100002452.
- Lebrikizumab type Unit109465459.
- Lebrikizumab type Drug.
- Lebrikizumab type DrugProduct.
- Lebrikizumab type FunctionalSubstance.
- Lebrikizumab comment "Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppresive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. The drug was created by Tanox under the name TNX-650, and a phase I clinical trial for refractory Hodgkin’s lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a Phase II clinical trial for the treatment of asthma.".
- Lebrikizumab label "Lebrikizumab".
- Lebrikizumab label "Lebrikizumab".
- Lebrikizumab label "لبريكيزوماب".
- Lebrikizumab sameAs Lebrikizumab.
- Lebrikizumab sameAs m.02wx78d.
- Lebrikizumab sameAs Q3829321.
- Lebrikizumab sameAs Q3829321.
- Lebrikizumab sameAs Lebrikizumab.
- Lebrikizumab wasDerivedFrom Lebrikizumab?oldid=604290219.
- Lebrikizumab isPrimaryTopicOf Lebrikizumab.